AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Rare and Atypical Diabetes Network

Recruitingn/aAges any - anyAllUniversity of South Florida
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: The following criteria or phenotypes will be considered for suspecting "atypical" participants: * Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese * Mendelian pattern, especially with early onset (\<18 years old) * Syndromic (multiple systems involved) * Lipodystrophic * Extremes of BMI * "Mitochondrial" characteristics (e.g., myopathy, hearing deficits) * Non-progressive * Rapidly progressive ("fulminant") * Low insulin requirements (\<0.5 u/kg/day) * Cyclical hyperglycemia with periods of remission * Lean persons with polycystic ovarian syndrome (PCOS) * History of gestational diabetes (GDM) when lean * Lean insulin-resistant persons * If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function): oA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype) Exclusion Criteria: * Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes * Refusal of consent for genetic testing * Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded) * Women who are currently pregnant
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

13 sites
University of Colorado- Denver
Aurora, United States
University of Chicago
Chicago, United States
Indiana University
Indianapolis, United States
University of Maryland
Baltimore, United States
Massachusetts General Hospital (MGH)
Boston, United States
University of Michigan
Ann Arbor, United States
Washington University in St. Louis
St Louis, United States
SUNY Downstate Health Sciences University
Brooklyn, United States

โ€ฆand 5 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy